{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:51:59Z","timestamp":1765356719787,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.surg.2020.03.021","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T17:02:33Z","timestamp":1590858153000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of multikinase inhibitor approval on survival and physician practice patterns in advanced or metastatic medullary thyroid carcinoma"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0167-8804","authenticated-orcid":false,"given":"Jessica W.","family":"Thiesmeyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Limberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dessislava","family":"Stefanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"Bains","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Beninato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasa","family":"Zarnegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas J.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-688X","authenticated-orcid":false,"given":"Brendan M.","family":"Finnerty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2020.03.021_bib1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.surg.2020.03.021_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.surg.2020.03.021_bib3","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2020.03.021_bib4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.28661","article-title":"RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma","volume":"120","author":"Krampitz","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2020.03.021_bib5","first-page":"1619","article-title":"Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence","volume":"81","author":"Romei","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2020.03.021_bib6","first-page":"3088","article-title":"Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas","volume":"80","author":"Zedenius","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2020.03.021_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/1097-0215(20010120)95:1<62::AID-IJC1011>3.0.CO;2-1","article-title":"Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma","volume":"95","author":"Schilling","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.surg.2020.03.021_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2020.03.021_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2265.1998.00392.x","article-title":"Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients","volume":"48","author":"Modigliani","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.surg.2020.03.021_bib10","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2020.03.021_bib11","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug\u00a0Administration drug approval summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.surg.2020.03.021_bib12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jamcollsurg.2004.12.011","article-title":"Extent of disease and practice patterns for medullary thyroid cancer","volume":"200","author":"Kebebew","year":"2005","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.surg.2020.03.021_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.6004\/jnccn.2010.0042","article-title":"Medullary thyroid carcinoma: management of lymph node metastases","volume":"8","author":"Moley","year":"2010","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.surg.2020.03.021_bib14","first-page":"8532","article-title":"The role of radiation therapy in the treatment of\u00a0medullary thyroid cancer","author":"Terezakis","year":"2010","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.surg.2020.03.021_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-2008-1046781","article-title":"Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium","volume":"40","author":"Matuszczyk","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.surg.2020.03.021_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","article-title":"Medullary thyroid carcinoma","volume":"22","author":"Pacini","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.surg.2020.03.021_bib17","unstructured":"Caprelsa. Prescribing information, 2014. AstraZeneca Pharmaceuticals LP. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022405s007lbl.pdf. Accessed February 2, 2020."},{"key":"10.1016\/j.surg.2020.03.021_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","article-title":"Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions","volume":"14","author":"Morabito","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.surg.2020.03.021_bib19","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.surg.2020.03.021_bib20","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2020.03.021_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.surg.2020.03.021_bib22","unstructured":"National Cancer Database, 2020. American College of Surgeons. Available at: https:\/\/www.facs.org\/quality-programs\/cancer\/ncdb\/about. Accessed January 30, 2020."},{"key":"10.1016\/j.surg.2020.03.021_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-19-0259","article-title":"Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response","volume":"27","author":"Valerio","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.surg.2020.03.021_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/a-1023-4214","article-title":"Anti-tumor activity and safety of multikinase inhibitors in advanced and\/or metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials","volume":"52","author":"Tsoli","year":"2020","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.surg.2020.03.021_bib26","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1210\/jc.2019-00915","article-title":"National treatment practice for adrenocortical carcinoma: have they changed and have we made any progress?","volume":"104","author":"Tierney","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020301641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606020301641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:54:43Z","timestamp":1758538483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606020301641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0039606020301641"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2020.03.021","relation":{},"ISSN":["0039-6060"],"issn-type":[{"type":"print","value":"0039-6060"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of multikinase inhibitor approval on survival and physician practice patterns in advanced or metastatic medullary thyroid carcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2020.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}